IPOs

Micro-cap immuno-oncology biotech Kiromic BioPharma prices IPO at $12 low end

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, raised $15 million by offering 1.3 million shares at $12, the low end of the range of $12 to $14.

Kiromic BioPharma plans to list on the Nasdaq under the symbol KRBP. ThinkEquity acted as sole bookrunner on the deal.

The article Micro-cap immuno-oncology biotech Kiromic BioPharma prices IPO at $12 low end originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

KRBP

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More